Halozyme Therapeutics Inc (HALO)
39.12
+0.15
(+0.38%)
USD |
NASDAQ |
Apr 24, 16:00
39.10
-0.02
(-0.04%)
After-Hours: 20:00
Halozyme Therapeutics Free Cash Flow (Quarterly): 99.76M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 99.76M |
| September 30, 2023 | 129.47M |
| June 30, 2023 | 68.46M |
| March 31, 2023 | 75.59M |
| December 31, 2022 | 80.11M |
| September 30, 2022 | 68.63M |
| June 30, 2022 | 39.26M |
| March 31, 2022 | 47.31M |
| December 31, 2021 | 82.36M |
| September 30, 2021 | 121.24M |
| June 30, 2021 | 36.36M |
| March 31, 2021 | 58.03M |
| December 31, 2020 | 49.22M |
| September 30, 2020 | 5.908M |
| June 30, 2020 | 2.779M |
| March 31, 2020 | -4.958M |
| December 31, 2019 | -27.27M |
| September 30, 2019 | -30.69M |
| June 30, 2019 | -26.15M |
| March 31, 2019 | -5.351M |
| December 31, 2018 | 7.389M |
| September 30, 2018 | -19.26M |
| June 30, 2018 | -19.28M |
| March 31, 2018 | -23.02M |
| December 31, 2017 | 152.39M |
| Date | Value |
|---|---|
| September 30, 2017 | 20.10M |
| June 30, 2017 | -17.23M |
| March 31, 2017 | -22.56M |
| December 31, 2016 | -16.21M |
| September 30, 2016 | -9.172M |
| June 30, 2016 | -14.01M |
| March 31, 2016 | -14.12M |
| December 31, 2015 | -16.83M |
| September 30, 2015 | -17.32M |
| June 30, 2015 | 8.678M |
| March 31, 2015 | -13.97M |
| December 31, 2014 | -1.175M |
| September 30, 2014 | -13.55M |
| June 30, 2014 | -16.12M |
| March 31, 2014 | -18.04M |
| December 31, 2013 | -16.58M |
| September 30, 2013 | -12.74M |
| June 30, 2013 | -11.04M |
| March 31, 2013 | -11.28M |
| December 31, 2012 | -17.41M |
| September 30, 2012 | -14.47M |
| June 30, 2012 | -14.46M |
| March 31, 2012 | -19.36M |
| December 31, 2011 | -14.06M |
| September 30, 2011 | -13.48M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-30.69M
Minimum
Sep 2019
129.47M
Maximum
Sep 2023
46.07M
Average
49.22M
Median
Dec 2020
Free Cash Flow (Quarterly) Benchmarks
| Johnson & Johnson | 5.804B |
| Globus Medical Inc | 81.79M |
| Denali Therapeutics Inc | -100.89M |
| AIM ImmunoTech Inc | -9.956M |
| Protalix BioTherapeutics Inc | 3.345M |